Pharmaceutical Technology21 天
Tinostamustine by Mundipharma EDO for Mantle Cell Lymphoma: Likelihood of Approval
The therapeutic candidate is administered by intravenous and parenteral route. NL-101 is a hybrid fusion molecule in which the side chain of bendamustine was replaced with the hydroxamic acid of HDACi ...
Pharmaceutical Technology21 天
Tinostamustine by Northlake International for Multiple Myeloma (Kahler Disease): Likelihood ...
The therapeutic candidate is administered by intravenous and parenteral route. NL-101 is a hybrid fusion molecule in which the side chain of bendamustine was replaced with the hydroxamic acid of HDACi ...